Synuclein, gamma, Recombinant, Human, Western Blot Positive Control (BCSG1, SYN)

Product Overview

• Article Name: Synuclein, gamma, Recombinant, Human, Western Blot Positive Control (BCSG1, SYN)
• Biozol Catalog Number: USB-S9502-10B
• Supplier Catalog Number: S9502-10B
• Alternative Catalog Number: USB-S9502-10B-100
• Manufacturer: US Biological
• Category: Molekularbiologie
• Application: WB

Product Description

Parkinsons disease (PD) is a common neurodegenerative disorder with a lifetime incidence of approximately 2 percent, the clinical manifestations of this neurodegenerativedisorder include resting tremor, muscular rigidity, bradykinesia,and postural instability. A relatively specific pathological featureaccompanying the neuronal degeneration is an intracytoplasmicinclusion body, known as the Lewy body. A mutation was identified in the -synuclein gene, which codesfor a presynaptic protein thought to be involved in neuronal plasticity, this mutation may cause a conformational change that renders -synuclein more prone to self aggregation and deposition in Lewy bodies, which finally leads to oxidative stress and misfolding of -synuclein. Parkin gene, mutations in this gene are reported in early autosomal-recessive form of PD, however these mutations do not degenerate Lewy bodies. The Parkin gene product (Parkin) is involved in protein degradation as a ubiquitin protein ligase, the known substrates of Parkin include Pael-R (Parkin-associated endothelin receptor-like receptor), Ubiquitination of Pael-R by Parkin leads to its degradation in the proteasome, however failure to ubiquitinate it leads to death of neuron. The synuclein exists in 3 isoform -syn (chrm 4q21), a 140aa protein, implicated in pathogenesis of PD and related neurodegenerative disorders, it is mainly expressed in brain specifically in neuronal cell bodies and synapses. The 134 aa b-syn (chrm 5q35) is homologous to 14kD bovine phosphoneuroprotein 14, SCNB has been shown to be highly expressed in the substantia nigra of the brain. Recently a new isoform termed g-synuclein (SNCG) or breast cancer gene 1 (BCG1) has been cloned (human 127 aa (chrm 10q23), rat/mouse 123 aa). Higher levels of expression of SNCG have been reported in advanced breast carcinomas. All three synuclein show ~40% identity. Human Gamma synuclein recombinant protein, an acidic neuronal protein of 127aa. It is up regulated in the majority of late-stage breast and ovarian cancers, it promotes cancer cell survival and inhibits stress and chemotherapy drug induced apoptosis by modulating MAP kinase pathways. Source: Human recombinant purified gamma-synuclein protein (mol wt 15-16kD) Applications: Suitable for use in Western Blot as a positive control. Other applications not tested. Recommended Dilution: Western Blot: Load 10ul/lane for good visibility with antibody Cat S9501-05A. Optimal dilutions to be determined by the researcher. Note: SDS may crystallize in cold conditions. It should redissolve by warming before taking it from the stock. It should be heated once prior to loading on gels. If the product has been stored for several weeks, then it may be preferable to add 5ul of fresh 2X sample buffer per 10ul of solution prior to heating and loading on gels. This preparation is not biologically active. It is not suitable for ELISA or other applications where native protein is required. This preparation is intended for qualitative purpose and not to serve as standard of known concentration. Do not freeze, thaw, or heat repeatedly Storage and Stability: Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile buffer or ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Product Properties

• Purity: Purified
• Form: Supplied as a lyophilized powder from PBS, 0.05% sodium azide.